-
2
-
-
0025847974
-
The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis
-
Morfini M, Lee M, Messori A. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Thromb Haemost 1991; 66: 384–6.
-
(1991)
Thromb Haemost
, vol.66
, pp. 384-386
-
-
Morfini, M.1
Lee, M.2
Messori, A.3
-
3
-
-
79951472629
-
Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia
-
Collins PW, Fischer K, Morfini M, Blanchette VS, Bjorkman S. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia 2011; 17: 2–10.
-
(2011)
Haemophilia
, vol.17
, pp. 2-10
-
-
Collins, P.W.1
Fischer, K.2
Morfini, M.3
Blanchette, V.S.4
Bjorkman, S.5
-
4
-
-
70349229281
-
Pharmacokinetics and dose requirements of factor VIII over the age range 3–74 years
-
Björkman S, Folkesson A, Jönsson S. Pharmacokinetics and dose requirements of factor VIII over the age range 3–74 years. Eur J Clin Pharmacol 2009; 65: 989–98.
-
(2009)
Eur J Clin Pharmacol
, vol.65
, pp. 989-998
-
-
Björkman, S.1
Folkesson, A.2
Jönsson, S.3
-
5
-
-
84992741171
-
The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A
-
McEneny-King A, Iorio A, Foster G, Edginton AN. The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A. Expert Opin Drug Metab Toxicol 2016; 12: 1313–21.
-
(2016)
Expert Opin Drug Metab Toxicol
, vol.12
, pp. 1313-1321
-
-
McEneny-King, A.1
Iorio, A.2
Foster, G.3
Edginton, A.N.4
-
6
-
-
85019821641
-
What is the role for population pharmacokinetics in hemophilia?
-
Iorio A, McEneny-King A, Keepanasseril A, Foster G, Edginton A. What is the role for population pharmacokinetics in hemophilia? Int J Pharmacokinet 2017; 2: 125–36.
-
(2017)
Int J Pharmacokinet
, vol.2
, pp. 125-136
-
-
Iorio, A.1
McEneny-King, A.2
Keepanasseril, A.3
Foster, G.4
Edginton, A.5
-
7
-
-
84873038634
-
Measurement of factor VIII pharmacokinetics in routine clinical practice
-
Björkman S, Collins P. Measurement of factor VIII pharmacokinetics in routine clinical practice. J Thromb Haemost 2013; 11: 180–2.
-
(2013)
J Thromb Haemost
, vol.11
, pp. 180-182
-
-
Björkman, S.1
Collins, P.2
-
8
-
-
84959422310
-
Population pharmacokinetics of plasma-derived factor IX: procedures for dose individualization
-
Brekkan A, Berntorp E, Jensen K, Nielsen EI, Jönsson S. Population pharmacokinetics of plasma-derived factor IX: procedures for dose individualization. J Thromb Haemost 2016; 14: 724–32.
-
(2016)
J Thromb Haemost
, vol.14
, pp. 724-732
-
-
Brekkan, A.1
Berntorp, E.2
Jensen, K.3
Nielsen, E.I.4
Jönsson, S.5
-
9
-
-
84929607738
-
Population pharmacokinetics of recombinant factor VIII Fc fusion protein
-
Nestorov I, Neelakantan S, Ludden TM, Li S, Jiang H, Rogge M. Population pharmacokinetics of recombinant factor VIII Fc fusion protein. Clin Pharmacol Drug Dev 2015; 4: 163–74.
-
(2015)
Clin Pharmacol Drug Dev
, vol.4
, pp. 163-174
-
-
Nestorov, I.1
Neelakantan, S.2
Ludden, T.M.3
Li, S.4
Jiang, H.5
Rogge, M.6
-
10
-
-
70350216170
-
Population pharmacokinetics of recombinant factor VIII:C (ReFacto) in adult HIV-negative and HIV-positive haemophilia patients
-
Karafoulidou A, Suarez E, Anastasopoulou I, Katsarou O, Kouramba A, Kotsi P, Zografidis A, Lukas JC. Population pharmacokinetics of recombinant factor VIII:C (ReFacto) in adult HIV-negative and HIV-positive haemophilia patients. Eur J Clin Pharmacol 2009; 65: 1121–30.
-
(2009)
Eur J Clin Pharmacol
, vol.65
, pp. 1121-1130
-
-
Karafoulidou, A.1
Suarez, E.2
Anastasopoulou, I.3
Katsarou, O.4
Kouramba, A.5
Kotsi, P.6
Zografidis, A.7
Lukas, J.C.8
-
11
-
-
84855853759
-
Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight
-
Bjorkman S, Oh M, Spotts G, Schroth P, Fritsch S, Ewenstein BM, Casey K, Fischer K, Blanchette VS, Collins PW. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood 2012; 119: 612–18.
-
(2012)
Blood
, vol.119
, pp. 612-618
-
-
Bjorkman, S.1
Oh, M.2
Spotts, G.3
Schroth, P.4
Fritsch, S.5
Ewenstein, B.M.6
Casey, K.7
Fischer, K.8
Blanchette, V.S.9
Collins, P.W.10
-
12
-
-
84900840847
-
Population pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) in patients with haemophilia B
-
Diao L, Li S, Ludden T, Gobburu J, Nestorov I, Jiang H. Population pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) in patients with haemophilia B. Clin Pharmacokinet 2014; 53: 467–77.
-
(2014)
Clin Pharmacokinet
, vol.53
, pp. 467-477
-
-
Diao, L.1
Li, S.2
Ludden, T.3
Gobburu, J.4
Nestorov, I.5
Jiang, H.6
-
13
-
-
84919491430
-
Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial
-
Collins PW, Young G, Knobe K, Karim FA, Angchaisuksiri P, Banner C, Gürsel T, Mahlangu J, Matsushita T, Mauser-Bunschoten EP, Oldenburg J, Walsh CE, Negrier C. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood 2014; 124: 3880–6.
-
(2014)
Blood
, vol.124
, pp. 3880-3886
-
-
Collins, P.W.1
Young, G.2
Knobe, K.3
Karim, F.A.4
Angchaisuksiri, P.5
Banner, C.6
Gürsel, T.7
Mahlangu, J.8
Matsushita, T.9
Mauser-Bunschoten, E.P.10
Oldenburg, J.11
Walsh, C.E.12
Negrier, C.13
-
14
-
-
84963542247
-
Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial
-
Santagostino E, Martinowitz U, Lissitchkov T, Pan-Petesch B, Hanabusa H, Oldenburg J, Boggio L, Negrier C, Pabinger I, von Depka Prondzinski M, Altisent C, Castaman G, Yamamoto K, Alvarez-Roman M-T, Voigt C, Blackman N, Jacobs I. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood 2016; 127: 1761–9.
-
(2016)
Blood
, vol.127
, pp. 1761-1769
-
-
Santagostino, E.1
Martinowitz, U.2
Lissitchkov, T.3
Pan-Petesch, B.4
Hanabusa, H.5
Oldenburg, J.6
Boggio, L.7
Negrier, C.8
Pabinger, I.9
von Depka Prondzinski, M.10
Altisent, C.11
Castaman, G.12
Yamamoto, K.13
Alvarez-Roman, M.-T.14
Voigt, C.15
Blackman, N.16
Jacobs, I.17
-
16
-
-
85020297137
-
Development of a web-accessible population pharmacokinetic service – hemophilia (WAPPS-Hemo): Study Protocol
-
Iorio A, Keepanasseril A, Foster G, Navarro-Ruan T, McEneny-King A, Edginton AN, Thabane L. Development of a web-accessible population pharmacokinetic service – hemophilia (WAPPS-Hemo): Study Protocol. JMIR Res Protoc 2016; 5: e239.
-
(2016)
JMIR Res Protoc
, vol.5
-
-
Iorio, A.1
Keepanasseril, A.2
Foster, G.3
Navarro-Ruan, T.4
McEneny-King, A.5
Edginton, A.N.6
Thabane, L.7
-
17
-
-
85019821659
-
Data analysis protocol for the development and evaluation of population pharmacokinetic models for incorporation into the web-accessible population pharmacokinetic service – hemophilia (WAPPS-Hemo)
-
McEneny-King A, Foster G, Iorio A, Edginton AN. Data analysis protocol for the development and evaluation of population pharmacokinetic models for incorporation into the web-accessible population pharmacokinetic service – hemophilia (WAPPS-Hemo). JMIR Res Protoc 2016; 5: e232.
-
(2016)
JMIR Res Protoc
, vol.5
-
-
McEneny-King, A.1
Foster, G.2
Iorio, A.3
Edginton, A.N.4
-
18
-
-
85009135401
-
® in patients with severe haemophilia A without inhibitors
-
® in patients with severe haemophilia A without inhibitors. Haemophilia 2017; 23: e50–4.
-
(2017)
Haemophilia
, vol.23
, pp. e50-e54
-
-
Álvarez-Román, M.T.1
Fernandez-Bello, I.2
de la Corte-Rodríguez, H.3
Hernández-Moreno, A.L.4
Martín-Salces, M.5
Butta-Coll, N.6
Rivas-Pollmar, M.I.7
Rivas-Muñoz, S.8
Jiménez-Yuste, V.9
-
19
-
-
59849093369
-
Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A
-
Collins PW, Blanchette VS, Fischer K, Björkman S, Oh M, Fritsch S, Schroth P, Spotts G, Astermark J, Ewenstein B. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost 2009; 7: 413–20.
-
(2009)
J Thromb Haemost
, vol.7
, pp. 413-420
-
-
Collins, P.W.1
Blanchette, V.S.2
Fischer, K.3
Björkman, S.4
Oh, M.5
Fritsch, S.6
Schroth, P.7
Spotts, G.8
Astermark, J.9
Ewenstein, B.10
-
20
-
-
84979085792
-
Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis
-
Valentino LA, Pipe SW, Collins PW, Blanchette VS, Berntorp E, Fischer K, Ewenstein BM, Oh M, Spotts G. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis. Haemophilia 2016; 22: 514–20.
-
(2016)
Haemophilia
, vol.22
, pp. 514-520
-
-
Valentino, L.A.1
Pipe, S.W.2
Collins, P.W.3
Blanchette, V.S.4
Berntorp, E.5
Fischer, K.6
Ewenstein, B.M.7
Oh, M.8
Spotts, G.9
-
21
-
-
85016641026
-
Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement
-
Iorio A, Iserman E, Blanchette V, Dolan G, Escuriola Ettingshausen C, Hermans C, Negrier C, Oldenburg J, Reininger A, Rodriguez-Merchan C, Spannagl M, Valentino LA, Young G, Steinitz-Trost KN, Gringeri A. Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement. Haemophilia 2017; 23: e170–e179.
-
(2017)
Haemophilia
, vol.23
, pp. e170-e179
-
-
Iorio, A.1
Iserman, E.2
Blanchette, V.3
Dolan, G.4
Escuriola Ettingshausen, C.5
Hermans, C.6
Negrier, C.7
Oldenburg, J.8
Reininger, A.9
Rodriguez-Merchan, C.10
Spannagl, M.11
Valentino, L.A.12
Young, G.13
Steinitz-Trost, K.N.14
Gringeri, A.15
-
22
-
-
84867166712
-
Association between physical activity and risk of bleeding in children with hemophilia
-
Broderick CR, Herbert RD, Latimer J, Barnes C, Curtin JA, Mathieu E, Monagle P, Brown SA. Association between physical activity and risk of bleeding in children with hemophilia. JAMA 2012; 308: 1452–9.
-
(2012)
JAMA
, vol.308
, pp. 1452-1459
-
-
Broderick, C.R.1
Herbert, R.D.2
Latimer, J.3
Barnes, C.4
Curtin, J.A.5
Mathieu, E.6
Monagle, P.7
Brown, S.A.8
-
23
-
-
84989315273
-
A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients
-
Hazendonk H, Fijnvandraat K, Lock J, Driessens M, van der Meer F, Meijer K, Kruip M, Gorkom BL -V., Peters M, de Wildt S, Leebeek F, Cnossen M, Mathot R. A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients. Haematologica 2016; 101: 1159–69.
-
(2016)
Haematologica
, vol.101
, pp. 1159-1169
-
-
Hazendonk, H.1
Fijnvandraat, K.2
Lock, J.3
Driessens, M.4
van der Meer, F.5
Meijer, K.6
Kruip, M.7
Gorkom, B.L.-V.8
Peters, M.9
de Wildt, S.10
Leebeek, F.11
Cnossen, M.12
Mathot, R.13
-
24
-
-
84975687550
-
Perioperative treatment of hemophilia A patients: Blood group O patients are at risk of bleeding complications
-
Hazendonk HCAM, Lock J, Mathôt RAA, Meijer K, Peters M, Laros-van Gorkom BAP, van der Meer FJM, Driessens MHE, Leebeek FWG, Fijnvandraat K, Cnossen MH. Perioperative treatment of hemophilia A patients: Blood group O patients are at risk of bleeding complications. J Thromb Haemost 2015; 14: 468–78.
-
(2015)
J Thromb Haemost
, vol.14
, pp. 468-478
-
-
Hazendonk, H.C.A.M.1
Lock, J.2
Mathôt, R.A.A.3
Meijer, K.4
Peters, M.5
Laros-van Gorkom, B.A.P.6
van der Meer, F.J.M.7
Driessens, M.H.E.8
Leebeek, F.W.G.9
Fijnvandraat, K.10
Cnossen, M.H.11
-
25
-
-
69449088981
-
Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients
-
Fischer K, Pendu R, van Schooten CJ, van Dijk K, Denis CV, van den Berg HM, Lenting PJ. Models for prediction of factor VIII half-life in severe haemophiliacs: distinct approaches for blood group O and non-O patients. PLoS ONE 2009; 4: e6745.
-
(2009)
PLoS ONE
, vol.4
-
-
Fischer, K.1
Pendu, R.2
van Schooten, C.J.3
van Dijk, K.4
Denis, C.V.5
van den Berg, H.M.6
Lenting, P.J.7
-
26
-
-
84976209150
-
A critical appraisal of one-stage and chromogenic assays of factor VIII activity
-
Peyvandi F, Oldenburg J, Friedman KD. A critical appraisal of one-stage and chromogenic assays of factor VIII activity. J Thromb Haemost 2016; 14: 248–61.
-
(2016)
J Thromb Haemost
, vol.14
, pp. 248-261
-
-
Peyvandi, F.1
Oldenburg, J.2
Friedman, K.D.3
-
27
-
-
84931956043
-
Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators
-
Dodt J, Hubbard AR, Wicks SJ, Gray E, Neugebauer B, Charton E, Silvester G. Potency determination of factor VIII and factor IX for new product labelling and postinfusion testing: challenges for caregivers and regulators. Haemophilia 2015; 21: 543–9.
-
(2015)
Haemophilia
, vol.21
, pp. 543-549
-
-
Dodt, J.1
Hubbard, A.R.2
Wicks, S.J.3
Gray, E.4
Neugebauer, B.5
Charton, E.6
Silvester, G.7
-
28
-
-
85020247012
-
Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates
-
Iorio A, Fischer K, Blanchette V, Rangarajan S, Young G, Morfini M. Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates. Thromb Haemost 2017; 117: 1023–30.
-
(2017)
Thromb Haemost
, vol.117
, pp. 1023-1030
-
-
Iorio, A.1
Fischer, K.2
Blanchette, V.3
Rangarajan, S.4
Young, G.5
Morfini, M.6
-
29
-
-
0035216180
-
Ways to fit a PK model with some data below the quantification limit
-
Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 2001; 28: 481–504.
-
(2001)
J Pharmacokinet Pharmacodyn
, vol.28
, pp. 481-504
-
-
Beal, S.L.1
-
30
-
-
52549112649
-
Likelihood based approaches to handling data below the quantification limit using NONMEM VI
-
Ahn JE, Karlsson MO, Dunne A, Ludden TM. Likelihood based approaches to handling data below the quantification limit using NONMEM VI. J Pharmacokinet Pharmacodyn 2008; 35: 401–21.
-
(2008)
J Pharmacokinet Pharmacodyn
, vol.35
, pp. 401-421
-
-
Ahn, J.E.1
Karlsson, M.O.2
Dunne, A.3
Ludden, T.M.4
|